Document Detail


Progression of preclinical diastolic dysfunction to the development of symptoms.
MedLine Citation:
PMID:  20350989     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Preclinical diastolic dysfunction (PDD) has been defined as subjects with normal systolic function, diastolic dysfunction but no symptoms of heart failure (HF). The clinical phenotype and natural history of the syndrome remains poorly defined. This study's objective was to determine the clinical phenotype and progression to HF in a group of patients with normal systolic function and moderate or severe diastolic dysfunction as determinate by Doppler criteria without any clinical diagnosis of HF according to the Framingham criteria or any symptoms of HF, specifically dyspnoea, oedema or fatigue at the time of echocardiography.
METHODS: The authors used resources of the Mayo Clinic echocardiography database to consecutively select among patients who had an echocardiogram in 2005, a cohort with moderate or severe diastolic dysfunction by Doppler criteria and EF >or=50%. Patients could not have a diagnosis of HF, or any HF symptoms-specifically dyspnoea, oedema or fatigue-at the time of echocardiography; nor grade 3 or greater valvular dysfunction (except tricuspid valve). A total of 82 patients had their medical chart reviewed. Primary endpoint was the time to the development of (1) HF according to the Framingham criteria or (2) any symptoms of dyspnoea, oedema or fatigue.
RESULTS: The mean age of the cohort of PDD subjects was 69+/-10 years with a female (67%) preponderance. Presence of hypertension was 76%, coronary artery disease was 29%, paroxysmal atrial fibrillation was 26%, estimated creatinine clearance <60 ml/min was 51%. The 2-year cumulative probability of development of HF according to the Framingham criteria was 1.9%; however, the 2-year cumulative probability of development of any symptoms was 31.1%. The 2-year cumulative probability for cardiac hospitalisation was 21.2%. Peripheral vascular disease and hypertension were independently associated with increased likelihood for the development of symptoms.
CONCLUSION: The study demonstrates that hypertension, hyperlipidaemia, CAD and renal dysfunction are prevalent in patients with PDD. More importantly, although the progression to the development of clinical HF over 2 years was low, there was a moderate degree of progression to development of symptoms and cardiac hospitalisations over 2 years. Based on the finding that only PVD and hypertension were independently associated with the progression to the development of symptoms in subject with PDD, the authors speculate that ventricular-arterial interaction may be important to the progression of diastolic dysfunction to the development of symptoms.
Authors:
Daniel D Correa de Sa; David O Hodge; Joshua P Slusser; Magaret M Redfield; Robert D Simari; John C Burnett; Horng H Chen
Related Documents :
16877989 - Evaluation of cardiac function by tissue doppler imaging in children with chronic hepat...
9559969 - Effect of regional myocardial perfusion abnormalities on regional myocardial early dias...
7249299 - Impaired left ventricular diastolic filling in patients with coronary artery disease: a...
3180399 - Modified fontan procedure for biventricular hearts with complex forms of double-outlet ...
3267719 - Significance of systolic time intervals in predicting prognosis of primary pulmonary hy...
3112859 - Left ventricular function in adults with atrial septal defect.
9093729 - Clinical characteristics of severe peripheral neuropathy induced by docetaxel (taxotere).
12605659 - Long-term hydroxyurea therapy in beta-thalassaemia patients.
10990549 - Upper extremity deep venous thrombosis: an underrecognized manifestation of a hypercoag...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  96     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-30     Completed Date:  2010-06-03     Revised Date:  2011-07-27    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  528-32     Citation Subset:  AIM; IM    
Affiliation:
Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Atrial Fibrillation / complications
Cohort Studies
Coronary Disease / complications
Disease Progression
Female
Follow-Up Studies
Heart Failure, Diastolic / etiology*,  therapy
Hospitalization
Humans
Hyperlipidemias / complications
Hypertension / complications
Male
Myocardial Infarction / complications
Peripheral Vascular Diseases / complications
Phenotype
Renal Insufficiency / complications
Grant Support
ID/Acronym/Agency:
HL76611-04-P40/HL/NHLBI NIH HHS; P01 HL076611-040004/HL/NHLBI NIH HHS; P01 HL076611-050003/HL/NHLBI NIH HHS; R01 HL084155-03/HL/NHLBI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early treatment with clarithromycin attenuates rat autoimmune myocarditis via inhibition of matrix m...
Next Document:  Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular s...